Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy
Language English Country United States Media print-electronic
Document type Comparative Study, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
PubMed
26415085
DOI
10.1056/nejmoa1508913
Knihovny.cz E-resources
- MeSH
- Gestational Age MeSH
- Cognition * drug effects radiation effects MeSH
- Infant MeSH
- Humans MeSH
- Pregnancy Complications, Neoplastic * drug therapy MeSH
- Infant, Premature psychology MeSH
- Infant, Low Birth Weight MeSH
- Infant, Newborn MeSH
- Birth Weight drug effects radiation effects MeSH
- Child, Preschool MeSH
- Antineoplastic Agents adverse effects MeSH
- Radiotherapy adverse effects MeSH
- Growth MeSH
- Heart anatomy & histology physiology MeSH
- Case-Control Studies MeSH
- Pregnancy MeSH
- Child Development * drug effects radiation effects MeSH
- Prenatal Exposure Delayed Effects * MeSH
- Check Tag
- Infant MeSH
- Humans MeSH
- Male MeSH
- Infant, Newborn MeSH
- Child, Preschool MeSH
- Pregnancy MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- Antineoplastic Agents MeSH
BACKGROUND: Data on the long-term outcome of children who are exposed to maternal cancer with or without treatment during pregnancy are lacking. METHODS: In this multicenter case-control study, we compared children whose mothers received a diagnosis of cancer during the pregnancy with matched children of women without a cancer diagnosis. We used a health questionnaire and medical files to collect data regarding neonatal and general health. All children were prospectively assessed (by means of a neurologic examination and the Bayley Scales of Infant Development) at 18 months, 36 months, or both. A cardiac assessment was performed at 36 months. RESULTS: A total of 129 children (median age, 22 months; range, 12 to 42) were included in the group whose mother had cancer (prenatal-exposure group) with a matching number in the control group. During pregnancy, 96 children (74.4%) were exposed to chemotherapy (alone or in combination with other treatments), 11 (8.5%) to radiotherapy (alone or in combination), 13 (10.1%) to surgery alone, 2 (1.6%) to other drug treatments, and 14 (10.9%) to no treatment. Birth weight was below the 10th percentile in 28 of 127 children (22.0%) in the prenatal-exposure group and in 19 of 125 children (15.2%) in the control group (P=0.16). There was no significant between-group difference in cognitive development on the basis of the Bayley score (P=0.08) or in subgroup analyses. The gestational age at birth was correlated with the cognitive outcome in the two study groups. Cardiologic evaluation among 47 children at 36 months of age showed normal cardiac findings. CONCLUSIONS: Prenatal exposure to maternal cancer with or without treatment did not impair the cognitive, cardiac, or general development of children in early childhood. Prematurity was correlated with a worse cognitive outcome, but this effect was independent of cancer treatment. (Funded by Research Foundation-Flanders and others; ClinicalTrials.gov number, NCT00330447.).
References provided by Crossref.org
Association of Chemotherapy Timing in Pregnancy With Congenital Malformation
Is It Possible to Personalize the Diagnosis and Treatment of Breast Cancer during Pregnancy?
Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy
Pregnancy and Cancer: the INCIP Project
ClinicalTrials.gov
NCT00330447
